No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Immutep Notches Upward on First Lung Cancer Patient Dosing
Immutep Doses First Patient in Phase 3 Trial of Non-Small Cell Lung Cancer Combination Therapy Candidate
Immutep Ltd (PRRUF) Receives a Buy From Canaccord Genuity
Immutep Ltd Reports Increased Income Amid Rising R&D Costs
Immutep Target Price Raised 5.0% to A$2.10/Share by Jefferies>IMM.AU
Immutep Ltd: Half Yearly Report and Accounts